RBFC
ADMA icon

Roman Butler Fullerton & Co’s ADMA Biologics ADMA Stock Holding History

Roman Butler Fullerton & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,591
Closed -$1.36M – 243
2025
Q1 		$1.36M Sell
61,591
-32,168
-34% -$556K 0.53% 45
2024
Q4 		$1.52M Sell
93,759
-13,867
-13% -$261K 0.48% 55
2024
Q3 		$1.78M Buy
107,626
+76,121
+242% +$1.18M 0.54% 46
2024
Q2 		$378K Buy
+31,505
New +$264K 0.12% 168

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Roman Butler Fullerton & Co's ADMA Position: Q2 2025 in Review

Roman Butler Fullerton & Co sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 61,591 shares — an estimated $1.36M sold.

Roman Butler Fullerton & Co first reported a position in ADMA in Q2 2024 and held it in 4 quarters. The position peaked at $1.78M in Q3 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Roman Butler Fullerton & Co reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 61,591 ADMA Biologics shares in Q2 2025, an estimated $1.36M.
  • Roman Butler Fullerton & Co first reported a position in ADMA Biologics in Q2 2024 and held it in 4 quarters.
  • Roman Butler Fullerton & Co's ADMA Biologics position peaked at $1.78M in Q3 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2025, filed 30 Jul 2025.